Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02162888
Title A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eagle Pharmaceuticals, Inc.
Indications

hematologic cancer

Advanced Solid Tumor

Therapies

Bendamustine

Age Groups: adult
Covered Countries USA


No variant requirements are available.